| Literature DB >> 34258585 |
Joaquin Mateo1, Rana McKay2, Wassim Abida3, Rahul Aggarwal4, Joshi Alumkal5, Ajjai Alva5, Felix Feng4, Xin Gao6, Julie Graff7, Maha Hussain8, Fatima Karzai9, Bruce Montgomery10, William Oh11, Vaibhav Patel11, Dana Rathkopf3, Matthew Rettig12, Nikolaus Schultz3, Matthew Smith6, David Solit3, Cora Sternberg13, Eliezer Van Allen14, David VanderWeele8, Jake Vinson15, Howard R Soule16, Arul Chinnaiyan5, Eric Small4, Jonathan W Simons16, William Dahut9, Andrea K Miyahira16, Himisha Beltran17.
Abstract
Despite advances in prostate cancer screening and treatment, available therapy options, particularly in later stages of the disease, remain limited and the treatment-resistant setting represents a serious unmet medical need. Moreover, disease heterogeneity and disparities in patient access to medical advances result in significant variability in outcomes across patients. Disease classification based on genomic sequencing is a promising approach to identify patients whose tumors exhibit actionable targets and make more informed treatment decisions. Here we discuss how we can accelerate precision oncology to inform broader genomically-driven clinical decisions for men with advanced prostate cancer, drug development and ultimately contribute to new treatment paradigms.Entities:
Mesh：
Substances：
Year: 2020 PMID： 34258585 PMCID： PMC8274325 DOI： 10.1038/s43018-020-00141-0
Source DB: PubMed Journal: Nat Cancer ISSN： 2662-1347